Jens W. Kindtler

Thrombologic ApS provides medical research and develops therapeutics. The firm develops a new therapy for prevention and treatment of multiple organ failure in Intensive care unit (ICU) patients. The company was founded in December 2009 and is headquartered in Copenhagen, Denmark.

Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase.

BI Technology A/S (BI-T) is a venture capital firm founded in 1969. The firm is headquartered in Copenhagen, Denmark.

SmartBead Technologies Ltd. used to provide drug development and research services. It used to develop medical diagnostic products based on multiplexing technology and ultraplex, which enables bar coding at a molecular level. The company was founded in 2000 and was headquartered in Cambridge, UK.

Pronostics Ltd. operates as a clinical diagnostics company. It offers diagnostic and disease monitoring applications. The company’s products include UltraPlex line of automated multiplexing solutions, such as UltraPlex multiplexed assays to multiplex a range of assays for applications in direct immunoassay; and UltraPlex ANA, a barcoded immunoassay for testing of autoimmune disease biomarkers that allows hospitals and laboratories to perform automated profiles of patient. The company was founded in 2000 and is headquartered in Cambridge, the United Kingdom.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.